For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Cat B 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background.
Cat B 680 FAST is a Cathepsin B activatable fluorescent agent that is optically silent upon injection and produces fluorescent signal after cleavage by Cathepsin B produced by inflammatory cells and tumor cells. Cat B 680 FAST may be used to monitor inflammation, tumor activity, progression of disease and the efficacy of therapeutic treatment in applications such as oncology, inflammation, cardiovascular disease and some neurological diseases.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||Cat B FAST|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
A novel NIR dye for in vivo temporal tracking of labeled macrophages to sites of acute inflammation
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.
Cat B™ 680 FAST ( NEV11112) IN VIVO IMAGING PROTOCOL ,
Cat B 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.